Cargando…

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Immune checkpoint blockade (ICB) therapy has provided clinical benefits for patients with advanced non-small-cell lung cancer (NSCLC), but the majority still do not respond. Although a few biomarkers of ICB treatment response have been developed, the predictive power of these biomarkers showed subst...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zedong, Zhou, Yao, Huang, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733693/
https://www.ncbi.nlm.nih.gov/pubmed/35003141
http://dx.doi.org/10.3389/fimmu.2021.813331
_version_ 1784627854655356928
author Jiang, Zedong
Zhou, Yao
Huang, Juan
author_facet Jiang, Zedong
Zhou, Yao
Huang, Juan
author_sort Jiang, Zedong
collection PubMed
description Immune checkpoint blockade (ICB) therapy has provided clinical benefits for patients with advanced non-small-cell lung cancer (NSCLC), but the majority still do not respond. Although a few biomarkers of ICB treatment response have been developed, the predictive power of these biomarkers showed substantial variation across datasets. Therefore, predicting response to ICB therapy remains a challenge. Here, we provided a concise combinatorial strategy for predicting ICB therapy response and constructed the ICB treatment signature (ITS) in lung cancer. The prediction performance of ITS has been validated in an independent ICB treatment cohort of NSCLC, where patients with higher ITS score were significantly associated with longer progression-free survival and better response. And ITS score was more powerful than traditional biomarkers, such as TMB and PD-L1, in predicting the ICB treatment response in NSCLC. In addition, ITS scores still had predictive effects in other cancer data sets, showing strong scalability and robustness. Further research showed that a high ITS score represented comprehensive immune activation characteristics including activated immune cell infiltration, increased mutation load, and TCR diversity. In conclusion, our practice suggested that the combination of biomarkers will lead to a better prediction of ICB treatment prognosis, and the ITS score will provide NSCLC patients with better ICB treatment decisions.
format Online
Article
Text
id pubmed-8733693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87336932022-01-07 A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer Jiang, Zedong Zhou, Yao Huang, Juan Front Immunol Immunology Immune checkpoint blockade (ICB) therapy has provided clinical benefits for patients with advanced non-small-cell lung cancer (NSCLC), but the majority still do not respond. Although a few biomarkers of ICB treatment response have been developed, the predictive power of these biomarkers showed substantial variation across datasets. Therefore, predicting response to ICB therapy remains a challenge. Here, we provided a concise combinatorial strategy for predicting ICB therapy response and constructed the ICB treatment signature (ITS) in lung cancer. The prediction performance of ITS has been validated in an independent ICB treatment cohort of NSCLC, where patients with higher ITS score were significantly associated with longer progression-free survival and better response. And ITS score was more powerful than traditional biomarkers, such as TMB and PD-L1, in predicting the ICB treatment response in NSCLC. In addition, ITS scores still had predictive effects in other cancer data sets, showing strong scalability and robustness. Further research showed that a high ITS score represented comprehensive immune activation characteristics including activated immune cell infiltration, increased mutation load, and TCR diversity. In conclusion, our practice suggested that the combination of biomarkers will lead to a better prediction of ICB treatment prognosis, and the ITS score will provide NSCLC patients with better ICB treatment decisions. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8733693/ /pubmed/35003141 http://dx.doi.org/10.3389/fimmu.2021.813331 Text en Copyright © 2021 Jiang, Zhou and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiang, Zedong
Zhou, Yao
Huang, Juan
A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title_full A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title_fullStr A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title_full_unstemmed A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title_short A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
title_sort combination of biomarkers predict response to immune checkpoint blockade therapy in non-small cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733693/
https://www.ncbi.nlm.nih.gov/pubmed/35003141
http://dx.doi.org/10.3389/fimmu.2021.813331
work_keys_str_mv AT jiangzedong acombinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer
AT zhouyao acombinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer
AT huangjuan acombinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer
AT jiangzedong combinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer
AT zhouyao combinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer
AT huangjuan combinationofbiomarkerspredictresponsetoimmunecheckpointblockadetherapyinnonsmallcelllungcancer